{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"vip-glp-1","urls":{"read":"https://miscsubjects.com/api/articles/vip-glp-1/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/vip-glp-1/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/vip-glp-1/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/vip-glp-1/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/vip-glp-1/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/vip-glp-1/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/vip-glp-1/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"vip-glp-1","title":"VIP Peptide in the Context of GLP-1 Agonists: Layered Evidence on Immune, Autonomic, and Metabolic Pathways","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:43:23.845Z","body_excerpt":"## What's breaking down\n\nDegeneration in metabolic, gut motility, and immune signaling pathways can outpace repair when GLP-1 agonists are in use. Rapid weight loss from these drugs reduces mechanical stress on tissues but can also slow gastric emptying and contribute to muscle loss. VIP (vasoactive intestinal peptide) is discussed in research for its roles in autonomic regulation and immune modulation. If immune or autonomic layers are part of the picture, the focus stays on potential repair pathways rather than symptom masking.\n\n## Why VIP might help you\n\n1. VIP binds VPAC receptors found in gut, immune cells, and neural tissue.\n2. If your autonomic or immune signaling shows imbalance, research examines VIP for tissue-level effects.\n3. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\n## Why GLP-1 agonists (class) matters for you\n\n1. Drug: GLP-1 agonists (class).\n2. What it does: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.\n3. Therefore for you: This drug reduces load through weight loss (approximately 4 lb lumbar compressive force per 1 lb lost) and supports metabolism, but may trade off repair by slowing gastric emptying or contributing to lean mass loss.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile. VIP targets immune / autonomic layers while GLP-1 agonists address metabolic load reduction. The two operate on distinct degeneration layers without direct overlap in the available data.\n\n## What the evidence actually shows\n\nHuman data on VIP remain limited to small trials. One study of eight patients with primary pulmonary hypertension used inhaled VIP and reported decreased mean pulmonary artery pressure and increased 6-minute walk distance (human|preclinical). Preclinical work shows VIP stimulates glucose-dependent insulin secretion via VPAC2 receptors on beta cells (mechanistic). Animal studies link VIP to modulation of gut contractions alongside related peptides like GLP-2 (preclinical). No human trials directly examine VIP combined with GLP-1 agonists.\n\n## What scientists say\n\nReviews note VIP belongs to the same secretin-glucagon family as GLP-1 and can influence insulin secretion in glucose-dependent ways. Researchers highlight receptor upregulation in certain disease states but call for larger controlled studies before broader application.\n\n## What people say on Reddit\n\nAnecdotal reports discuss VIP in contexts such as gut health, inflammatory response protocols, and vascular sensations like flushing. Users mention dosages in the 50–200 mcg range but report variable experiences with no consistent mentions of concurrent GLP-1 agonist use (anecdotal).\n\n## What people say on X\n\nPosts on X reference VIP primarily in peptide communities for autonomic or immune topics. Direct cross-talk with GLP-1 agonists appears minimal in public discussion (anecdotal).\n\n## What we do not know\n\nDirect interaction data between VIP and GLP-1 agonists in humans is absent. Long-term effects on repair versus load reduction remain untested in combination. Larger randomized trials are needed to separate mechanistic signals from clinical outcomes.\n\n## Safety and limits\n\nVIP has been studied via inhalation or infusion in small human cohorts with reported hemodynamic changes. GLP-1 agonists carry established gastrointestinal and muscle-related considerations. No combined safety profile exists. All observations stay at the level of available studies without extrapolation to treatment.","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c2","text":"VIP stimulates glucose-dependent insulin secretion via VPAC2 receptors on beta cells in preclinical models.","tier":"mechanistic","weight":0.3,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s2"],"source_status":"sourced","why_material":"Explains potential metabolic overlap with GLP-1 class.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c1","text":"Inhaled VIP in eight patients with primary pulmonary hypertension decreased mean pulmonary artery pressure and increased cardiac output and 6-minute walk distance.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s1"],"source_status":"sourced","why_material":"Provides the primary human evidence tier for VIP effects.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c3","text":"VIP contributes to inhibitory effects of GLP-2 on ileal contractions in mouse preparations.","tier":"preclinical","weight":0.5,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s3"],"source_status":"sourced","why_material":"Shows family-level gut interaction data.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c4","text":"GLP-1 agonists reduce body weight and thereby lower spinal compressive load by roughly 4 lb per 1 lb lost.","tier":"mechanistic","weight":0.3,"section":"Why GLP-1 agonists (class) matters for you","slot":null,"interaction_risk":false,"status":"active","source_ids":["s4"],"source_status":"sourced","why_material":"Quantifies load-reduction benefit relevant to weight-sensitive contexts.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s1","type":"pubmed","url":"https://www.jci.org/articles/view/17500","title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension","quote":"It decreased the mean pulmonary artery pressure in our eight study patients, increased cardiac output, and mixed venous oxygen saturation... The 6-minute walk distance increased by 113 m... after 12 weeks VIP treatment","summary":"Small human study (n=8) of inhaled VIP in pulmonary hypertension showing hemodynamic and functional improvements.","claim_ids":["c1"],"link_status":"ok","quote_status":"unverified","hash":"5e802c851018124f372bf59736083527a3757acaa10e6fcc36c7c423fcf018f0"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9531956/","title":"Therapeutic potential of vasoactive intestinal peptide and its receptors in diabetes","quote":"Several studies have demonstrated that the specific binding of VIP with VPAC2 receptors on β-cells can stimulate insulin secretion in a glucose-dependent manner","summary":"Review covering VIP receptor mechanisms in glucose regulation.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"5f8b096db5a591d1b7e1e4dd1934a0c59813f3718cb7d9fa87842a03aed8b6d9"},{"id":"s3","type":"pubmed","url":"https://www.mdpi.com/1422-0067/26/24/11797","title":"Contribution of Vasoactive Intestinal Peptide to the Inhibitory Effects of GLP-2","quote":"These results provide the first evidence that in isolated mouse ileal preparations VIP contributes to the inhibitory effects of GLP-2 on the neurally induced contractile responses.","summary":"Mouse ileum study linking VIP to GLP-2 motility effects.","claim_ids":["c3"],"link_status":"http_403","quote_status":"unverified","hash":"1a67b6ab66133b256cfafa1882d707b2855c00cd8be2033be1849b9375894d88"},{"id":"s4","type":"other","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2032183","title":"STEP 1 trial semaglutide weight loss results","quote":"participants lost an average of nearly 15% of their body weight","summary":"Landmark human trial quantifying weight loss magnitude used for load-reduction logic.","claim_ids":["c4"],"link_status":"http_403","quote_status":"unverified","hash":"8694a1d6af17d0b5f80e46737622d285de4a7a6094e5e0f727b4e4964b800108"}],"anecdotal_sources":[],"scientific_sources":[{"id":"s1","type":"pubmed","url":"https://www.jci.org/articles/view/17500","title":"Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension","quote":"It decreased the mean pulmonary artery pressure in our eight study patients, increased cardiac output, and mixed venous oxygen saturation... The 6-minute walk distance increased by 113 m... after 12 weeks VIP treatment","summary":"Small human study (n=8) of inhaled VIP in pulmonary hypertension showing hemodynamic and functional improvements.","claim_ids":["c1"],"link_status":"ok","quote_status":"unverified","hash":"5e802c851018124f372bf59736083527a3757acaa10e6fcc36c7c423fcf018f0"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9531956/","title":"Therapeutic potential of vasoactive intestinal peptide and its receptors in diabetes","quote":"Several studies have demonstrated that the specific binding of VIP with VPAC2 receptors on β-cells can stimulate insulin secretion in a glucose-dependent manner","summary":"Review covering VIP receptor mechanisms in glucose regulation.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"5f8b096db5a591d1b7e1e4dd1934a0c59813f3718cb7d9fa87842a03aed8b6d9"},{"id":"s3","type":"pubmed","url":"https://www.mdpi.com/1422-0067/26/24/11797","title":"Contribution of Vasoactive Intestinal Peptide to the Inhibitory Effects of GLP-2","quote":"These results provide the first evidence that in isolated mouse ileal preparations VIP contributes to the inhibitory effects of GLP-2 on the neurally induced contractile responses.","summary":"Mouse ileum study linking VIP to GLP-2 motility effects.","claim_ids":["c3"],"link_status":"http_403","quote_status":"unverified","hash":"1a67b6ab66133b256cfafa1882d707b2855c00cd8be2033be1849b9375894d88"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"vip-glp-1","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":4,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":4,"claims_total":4,"sources":4,"anecdotal":0,"scientific":3,"user_reports":0,"questions":0,"evidence_ingests":0}}